Zarei Allahdad, Yang Chang, Gibbs Jesse, Davis Jennifer L, Ballard Anna, Zeng Rong, Cox Linda, Veis Deborah J
Musculoskeletal Research Center Division of Bone and Mineral Diseases Department of Medicine Washington University School of Medicine St. Louis MO USA.
Department of Pathology and Immunology Washington University School of Medicine St. Louis MO USA.
JBMR Plus. 2018 Aug 23;3(1):14-22. doi: 10.1002/jbm4.10066. eCollection 2019 Jan.
Alternative NF-κB signaling promotes osteoclastogenesis and pathological bone loss, but the effect of sex on phenotype has not been explored. We disrupted alternative NF-κB signaling by deletion of upstream kinase NF-κB-inducing kinase (NIK) or NF-κB subunit RelB and found that both NIK-deficient and RelB-deficient female mice possessed more than twofold higher trabecular bone mass compared to controls, whereas no differences were observed in males. In vitro, RelB-deficient precursors from female mice showed a more severe osteoclast (OC) differentiation defect than male, while WT had no sex bias. Next, we asked whether pharmacologic activation of alternative NF-κB by inhibitor of apoptosis (IAP) antagonist BV6 has sex-dependent effects on bone. Unlike male mice that lost bone, female mice on BV6 for 4 weeks showed no changes in either trabecular bone mass or OC number. Because estrogen generally suppresses NF-κB, we hypothesized that estrogen protects bone from BV6 effects in vivo. Thus, we performed ovariectomy or sham surgery in female mice, then treated with BV6 or vehicle for 4 weeks. Although ovariectomy caused bone loss, BV6 did not have any additional impact, suggesting that direct estrogen effects do not cause resistance to BV6 in vivo. The osteopenic effects of IAP antagonists in males may have implications for their use in cancer therapy. © 2018 The Authors. published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
非经典核因子-κB信号通路促进破骨细胞生成和病理性骨质流失,但性别对其表型的影响尚未得到研究。我们通过缺失上游激酶核因子-κB诱导激酶(NIK)或核因子-κB亚基RelB来破坏非经典核因子-κB信号通路,发现与对照组相比,NIK缺陷型和RelB缺陷型雌性小鼠的骨小梁骨量高出两倍多,而雄性小鼠则未观察到差异。在体外,来自雌性小鼠的RelB缺陷型前体细胞显示出比雄性更严重的破骨细胞(OC)分化缺陷,而野生型则没有性别差异。接下来,我们询问凋亡抑制蛋白(IAP)拮抗剂BV6对非经典核因子-κB的药理激活是否对骨骼有性别依赖性影响。与骨质流失的雄性小鼠不同,接受BV6治疗4周的雌性小鼠的骨小梁骨量或OC数量均未发生变化。由于雌激素通常会抑制核因子-κB,我们推测雌激素在体内可保护骨骼免受BV6的影响。因此,我们对雌性小鼠进行卵巢切除术或假手术,然后用BV6或赋形剂治疗4周。尽管卵巢切除术导致骨质流失,但BV6没有任何额外影响,这表明雌激素的直接作用不会导致体内对BV6产生抗性。IAP拮抗剂对雄性小鼠的骨质减少作用可能对其在癌症治疗中的应用有影响。©2018作者。由Wiley Periodicals, Inc.代表美国骨与矿物质研究学会出版。